ORIC® Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

Company Overview - ORIC Pharmaceuticals, Inc. is a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance [3] - The company is headquartered in South San Francisco and San Diego, California [3] Product Candidates - ORIC's clinical stage product candidates include ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) targeting prostate cancer [3] - Another candidate is enozertinib (ORIC-114), a brain-penetrant inhibitor targeting EGFR exon 20 and atypical mutations, being developed for multiple genetically defined cancers [3] Upcoming Presentation - Jacob M. Chacko, M.D., the CEO of ORIC, will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 9:45 a.m. PT [1] - A live webcast of the presentation will be available on the company's investor section of the website, with a replay accessible for 90 days post-event [2]